Top Markets
Coin of the day
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Clasificación en acciones #33297
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Precio por acción
$0.4264
Última sincronización: 2022-09-14
Capitalización bursátil
$7.93M
Cambio (1 día)
-16.44%
Cambio (1 año)
0.00%
País
US
Comercio Caladrius Biosciences, Inc. (CLBS)

Categoría

Ratio P/S de Caladrius Biosciences, Inc. (CLBS)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Caladrius Biosciences, Inc., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Caladrius Biosciences, Inc. desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE